Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | RECQL | P46063 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 4/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | GFER | P55789 | 1/20 | 0.36 |
| ▸ | PDE4A | P27815 | 1/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.35 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12646078 | 0.83 | RAB9A (0.47) | RAB9AKMT2AALDH1A1MAPTSMN1; SMN2 | |
| Medazomide SCHEMBL1817436 | 0.82 | RAB9A (0.46) | RAB9AKMT2AALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL21395238 | 0.82 | RAB9A (0.42) | RAB9AKMT2AALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL29951027 | 0.81 | KDM4E (0.50) | RAB9AKMT2AALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL10045649 | 0.79 | RAB9A (0.43) | RAB9AKMT2AALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL21395281 | 0.77 | RAB9A (0.52) | RAB9AALDH1A1MAPTSMN1; SMN2RECQL | |
| SCHEMBL21394954 | 0.77 | RAB9A (0.52) | RAB9AKMT2AALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL21384226 | 0.75 | GAA (0.44) | KMT2AMAPTGAAPOLBATM | |
| SCHEMBL21395117 | 0.74 | RAB9A (0.50) | RAB9AKMT2AALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL21395265 | 0.74 | RAB9A (0.50) | RAB9AKMT2AALDH1A1MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11800869-B2 | Use of 6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxylic acid, 1-methyl 6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxylic acid and 1-alkyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxylic acid for improving growth performance in plants | Advanced Crop Chem LLP (US) | 2023-10-31 | — | — | US | claimed |
| EP-2200440-B1 | ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS | CRESTONE INC (US) | 2017-07-19 | — | — | EP | claimed |
| EP-2200440-A1 | ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS | Crestone, Inc. (US) | 2010-06-30 | — | — | EP | claimed |
| WO-2009015208-A1 | ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS | REPLIDYNE, INC. (US) | 2009-01-29 | — | — | WO | claimed |
| US-12180221-B2 | Compounds and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2024-12-31 | — | — | US | disclosed |
| CN-118084801-A | Compounds and uses thereof | 詹森药业有限公司 | 2024-05-28 | — | — | CN | disclosed |
| CN-118084800-A | Compounds and uses thereof | 詹森药业有限公司 | 2024-05-28 | — | — | CN | disclosed |
| CN-112312913-B | Compounds and uses thereof | 詹森药业有限公司 | 2024-03-08 | — | — | CN | disclosed |
| US-11800869-B2 | Use of 6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxylic acid, 1-methyl 6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxylic acid and 1-alkyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxylic acid for improving growth performance in plants | Advanced Crop Chem LLP (US) | 2023-10-31 | — | — | US | disclosed |
| US-11800869-B2 | Use of 6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxylic acid, 1-methyl 6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxylic acid and 1-alkyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxylic acid for improving growth performance in plants | Advanced Crop Chem LLP (US) | 2023-10-31 | — | — | US | disclosed |
| US-11800869-B2 | Use of 6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxylic acid, 1-methyl 6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxylic acid and 1-alkyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxylic acid for improving growth performance in plants | Advanced Crop Chem LLP (US) | 2023-10-31 | — | — | US | disclosed |
| US-20230078764-A1 | COMPOUNDS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2023-03-16 | — | — | US | disclosed |
| WO-2019183587-A1 | COMPOUNDS AND USES THEREOF | YUMANITY THERAPEUTICS, INC. (US) | 2019-09-26 | — | — | WO | disclosed |
| EP-2200440-B1 | ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS | CRESTONE INC (US) | 2017-07-19 | — | — | EP | disclosed |
| US-20110201615-A1 | TRIAZOLE BETA CARBOLINE DERIVATIVES AS ANTI-DIABETIC AGENTS | MERCK SHARP & DOHME CORP. | 2011-08-18 | — | — | US | disclosed |
| EP-2352373-A1 | TRIAZOLE BETA CARBOLINE DERIVATIVES AS ANTIDIABETIC COMPOUNDS | Merck Sharp & Dohme Corp. (US) | 2011-08-10 | — | — | EP | disclosed |
| US-20100184758-A1 | BETA CARBOLINE DERIVATIVES AS ANTIDIABETIC COMPOUNDS | MERCK SHARP & DOHME CORP. | 2010-07-22 | — | — | US | disclosed |
| EP-2200440-A1 | ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS | Crestone, Inc. (US) | 2010-06-30 | — | — | EP | disclosed |
| WO-2010051177-A1 | TRIAZOLE BETA CARBOLINE DERIVATIVES AS ANTIDIABETIC COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2010-05-06 | — | — | WO | disclosed |
| WO-2009015208-A1 | ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS | REPLIDYNE, INC. (US) | 2009-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184758-A1 | BETA CARBOLINE DERIVATIVES AS ANTIDIABETIC COMPOUNDS | GPR119, SSTR3, SSTR2 | RAB9A 3964/4885KMT2A 2164/4885ALDH1A1 1780/4885 |
| US-20230078764-A1 | COMPOUNDS AND USES THEREOF | NLN, BDNF, NQO1 | RAB9A 2778/4885KMT2A 587/4885ALDH1A1 293/4885 |
| US-12180221-B2 | Compounds and uses thereof | NLN, ACHE, CLN6 | RAB9A 2129/4885KMT2A 2479/4885ALDH1A1 656/4885 |
| US-20110201615-A1 | TRIAZOLE BETA CARBOLINE DERIVATIVES AS ANTI-DIABETIC AGENTS | GPR119, SSTR3, SSTR2 | RAB9A 3859/4885KMT2A 2271/4885ALDH1A1 2163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.